HOMECHOICE FOR DIALISE PERITONEAL BAXTER - Reg. 10068390123 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 BAXTER HOSPITALAR LTDA 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    779
  • 날짜
    2004-07-27
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    The possibility of excessive volume infusion can occur when the machine's initial "O. inrnic" drain alarm is set to "N", and a change in the expected drain volume is performed during the warning: "See drain inic XXXXML" . Essentially, if a very low initial drain alarm volume is programmed into the HomeChoice machine, incomplete initial drainage may occur. If this occurs followed by a complete infusion, the patient may present an excess of volume in his peritoneal cavity and possible adverse clinical reactions due to this excess. The first step to prevent this from occurring is to ensure that the initial drain alarm volume "Init Drain": is properly adjusted when initiating DPA therapy in HomeChoice and discourages subsequent changes in the program. The initial drain alarm volume "Initial Drain AI:" must be adjusted in the "Set Parameters" menu. 70% of the last volume infused in the HomeChoice or manual CAPD exchange is generally considered an initial percentage to determine the optimal setting of the initial drain alarm volume. If the initial drain alarm volume is set to a low volume in software versions 8.5 and later, HomeChoice will automatically alert the user to "View drain inc. XXXXML" at the start of each therapy. DPA. This will allow the user to temporarily increase the initial drainage alarm volume for this therapy, if necessary. This function was designed to meet the needs of those patients who started intermittent DPA therapy with fluid in their peritoneal cavity. If the patient initiates DPA therapy with fluid in their peritoneum, the initial drainage alarm volume should be increased to ensure incomplete initial drainage is not performed. If you have determined that a low initial drain alarm volume is most appropriate for your patient and the alarm volume is currently at "N", you must necessarily change the initial drain alarm volume that is "N" to "OML "in the" Set parameters "menu. If in future the patient's prescription requires that the initial drain alarm volume be temporarily increased using the "See drain inc .: XXXXML" function, this will ensure that the "Drain Low" function is activated. is fully active to prevent incomplete initial drainage. If you have any questions about this, please contact your Baxter Hospitalar Ltda representative, call the service center at 0800 12 55 22, option 3 or send an e-mail to Product Specialist, Edméia Mariani, edmeia_mariani @ baxter.com. The Technovigilance Unit / ANVISA will be following the corrective actions carried out on the machines with software versions 8.5 and later.
  • 원인
    Faced with a customer complaint, baxter has confirmed that machines with software versions 8.5 and later may eventually cause excessive volume infusion in patients.
  • 조치
    The company will be forwarding pages of the HomeChoice Patient Handbook that provide instructions on how to increase the initial drainage alarm volume, "AI drain inc:" permanently or temporarily, and providing a list of your patients performing home DPA. Ask me to review it and make sure it is complete. It further requests that this information be communicated to all its patients, based on the knowledge of its prescriptions and the operation of HomeChoice. Complete the response form that was sent to you and return it by fax to Baxter to the number indicated on the form itself. Returning this completed form will ensure that you have been informed and forwarded to all of your patients affected by this action.

Device

Manufacturer

  • Source
    ANVSANVISA